 Immunome Inc NASDAQ: IMNM has received an FDA clinical hold letter in response to its recently submitted IND requesting further information related to the preparation and administration of IMM-BCP-01 at clinical sites. The Company has already initiated the requisite work and expects to provide the requested information quickly. 